跳至主要内容
临床试验/NCT00087282
NCT00087282已完成2 期

A Non-Randomized Phase II Study of Sequential Irinotecan (CPT-11) And Flavopiridol In Patients With Advanced Hepatoma

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家开始时间: 2004年6月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
试验地点
1

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as irinotecan and flavopiridol, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving irinotecan together with flavopiridol works in treating patients with advanced liver cancer.

详细描述

OBJECTIVES:

Primary

  • Determine the time to progression in patients with advanced hepatocellular carcinoma treated with irinotecan and flavopiridol.

Secondary

  • Determine the response rate and overall survival in patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验